What is Zacks Research's Estimate for JAZZ Q1 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Zacks Research cut their Q1 2026 earnings estimates for Jazz Pharmaceuticals in a research report issued on Tuesday, April 29th. Zacks Research analyst S. Ganoria now forecasts that the specialty pharmaceutical company will post earnings of $3.11 per share for the quarter, down from their prior forecast of $3.13. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share.

Other analysts also recently issued research reports about the company. HC Wainwright upped their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Needham & Company LLC reiterated a "buy" rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Barclays reaffirmed an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Up 2.4 %

Shares of Jazz Pharmaceuticals stock traded up $2.87 during midday trading on Wednesday, reaching $120.05. 1,200,496 shares of the company's stock traded hands, compared to its average volume of 804,364. The company has a market cap of $7.40 billion, a price-to-earnings ratio of 16.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $148.06. The company's 50 day simple moving average is $122.63 and its 200 day simple moving average is $122.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Transactions at Jazz Pharmaceuticals

In other news, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Centre Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $464,000. Franklin Resources Inc. grew its position in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 13.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock valued at $4,420,000 after acquiring an additional 4,332 shares during the last quarter. Finally, BTC Capital Management Inc. boosted its stake in Jazz Pharmaceuticals by 9.4% during the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after acquiring an additional 4,271 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.